Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05202509 · ClinicalTrials.gov registry record · Phase 3
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
A Phase 3 study of Atherosclerotic Cardiovascular Disease, sponsored by NewAmsterdam Pharma.
- Active
- Registry status
- Phase 3
- Development phase
- 9,541
- Enrollment target
- 20
- Study locations
NCT05202509: Active Phase 3 study of Atherosclerotic Cardiovascular Disease, sponsored by NewAmsterdam Pharma.
NCT05202509 is a Phase 3 study of Atherosclerotic Cardiovascular Disease that is active but no longer recruiting, run by NewAmsterdam Pharma. The registered enrollment target is 9,541 participants, above the 7,113-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (34% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05202509, a Phase 3 study of Atherosclerotic Cardiovascular Disease, is active but no longer recruiting, sponsored by NewAmsterdam Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 9,541 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy.
Primary Outcome
To evaluate the effect of obicetrapib on the risk of MACE
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Obicetrapib
Study Locations (20)
Alabama
- Advanced Cardiovascular LLC - Alexander City
- Ascension - Cardiology Specialists of Birmingham - Birmingham
- Central Alabama Research - Birmingham
- Cardiovascular Associates of the Southeast, LLC - Birmingham
- Eastern Shore Research Institute, LLC - Fairhope
- The Heart Center Research - Huntsville
- Mobile Heart Specialists - Mobile
- Syed Research Consultants - Muscle Shoals
- Syed Research Consultants - Sheffield
California
- Advanced Research Center - Anaheim
- Westside Medical Associates of Los Angeles - Beverly Hills
- Hope Clinical Research LLC - Canoga Park
- Titan Medical Research - Oceanside - Encinitas
- Clinical Trials Research - Lincoln
- Torrance Clinical Research Institute Inc. - Lomita
Arizona
- Elite Clinical Studies - Phoenix
- Clinical Research Institute of Arizona, LLC - Sun City West
- Eclipse Clinical Research - Tucson
Arkansas
- NEA Baptist clinic - Jonesboro
- Cardiology and Medicine Clinic - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,541 participants |
| Start Date | 2022-02-07 |
| Est. Completion | 2026-11 |
| Phase | Phase 3 |
What the registry record for NCT05202509 still lists
NCT05202509 is an interventional study that assigns participants to a tested intervention. Its 9,541 participants enrollment target places it among the larger protocols in the corpus, above the 7,113-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (34% higher).
The record links to 1 condition, with Atherosclerotic Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05202509 names 20 study sites across 4 states, led by Alabama, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05202509 about?
NCT05202509 is a clinical study titled "Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease". This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy.
What is the current status of trial NCT05202509?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 9,541 participants. The study started on 2022-02-07. Estimated completion is 2026-11.
What conditions does trial NCT05202509 study?
This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease.
What interventions are being tested in trial NCT05202509?
The interventions under investigation include: Placebo (DRUG), Obicetrapib (DRUG).
Who is sponsoring clinical trial NCT05202509?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05202509 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerotic Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05202509's enrollment target sits among peer trials
9,541 6th of 21 higher than 16 of 21 other Atherosclerotic Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerotic Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Prevent Coronary Artery Disease Trial
RECRUITING · Phase 3
-
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
RECRUITING · Phase 3
-
Pelacarsen Roll-over Extension Program
RECRUITING · Phase 3
-
A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease
ACTIVE NOT RECRUITING · Phase 3
-
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
ACTIVE NOT RECRUITING · Phase 3
-
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05080673 · 9,500 participants · NA
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- NCT06284408 · 9,460 participants · NA
Centralized Screening Unit (CSU) at Montefiore-Einstein
- NCT06946355 · 9,119 participants · NA
Food-based Support for Hospitalized Children and Their Families
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI